Загрузка...
Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis
Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old female who developed odynophagia and bloody diarrhea following treatment with ocrelizu...
Сохранить в:
| Опубликовано в: : | Ann Gastroenterol |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Hellenic Society of Gastroenterology
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8079880/ https://ncbi.nlm.nih.gov/pubmed/33948072 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.20524/aog.2021.0582 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|